bell potter update, page-4

Interesting JM and thanks. Further to your thoughts - after pharmacokinetic trials are done a move to a combined II/III trial may be on the cards.
There will not be a lot left to test and trial, post pk trials, the main difference being that phase I's are usually done on the general population whereas phase II's and III's are done on a sub set specific to the drug - in this case, those in chronic pain.
So your theory sits well IMO. If we can test the same thing in a phase II, getting sufficient data for a pharma deal, do it quicker and cheaper, why not do it this way. A clever strategy.
A phase III, you would think is only testing the same thing, but on a much larger scale.
This strategy would only work imo if a major pharma was already dancing the tango with Esra or Harry, depending on their gender preference.